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Glycogen synthase kinase-3 (GSK-3) is a serine/threonine 
protein kinase that is known to mediate cancer cell death. Here, 
we show that B-cell lymphoma 2 (Bcl-2), an anti-apoptotic pro-
tein, is regulated by GSK-3 and that GSK-3-mediated regu-
lation of Bcl-2 is crucial for mitochondrial-dependent cell death 
in paclitaxel-stimulated cells. We demonstrate that MCF7 GSK- 
3 siRNA cells are more sensitive to cell death than MCF7 GFP 
control cells and that in the absence of GSK-3, Bcl-2 levels are 
reduced, a result enhanced by paclitaxel. Paclitaxel-induced 
JNK (c-Jun N-terminal kinase) activation is critical for Bcl-2 
modulation. In the absence of GSK-3, Bcl-2 was unstable in an 
ubiquitination-dependent manner in both basal- and paclitaxel- 
treated cells. Furthermore, we demonstrate that GSK-3-medi-
ated regulation of Bcl-2 influences cytochrome C release and 
mitochondrial membrane potential. Taken together, our data 
suggest that GSK-3-dependent regulation of Bcl-2 is crucial for 
mitochondria-dependent cell death in paclitaxel-mediated breast 
cancer therapy. [BMB Reports 2016; 49(1): 51-56]
INTRODUCTION
Glycogen synthase kinase-3 (GSK-3), a serine/threonine protein 
kinase, is involved in various cellular processes; it was first iden-
tified as an important regulator of glycogen synthesis (1). GSK-3 
has two isoforms, GSK-3 and GSK-3 (2), and two phosphor-
ylatable residues, Ser9 and Tyr216, whose phosphorylation de-
termines the activity of GSK-3 (3). Whereas GSK-3 activation 
generally requires phosphorylation on Tyr216; the Ser9 residue 
is critical for inhibition of activity (2, 3). GSK-3 is involved in 
multiple physiological responses such as cell survival, apopto-
sis, metabolism, diabetes, and homeostasis (2-7). In detail, 
knockout studies of GSK-3 have shown that it is crucial for 
Nuclear factor B (NFB-dependent cell survival (7); Ser9 phos-
phorylation of GSK-3 promotes cell survival via cAMP re-
sponse element binding protein (CREB)-dependent Bcl-2 ex-
pression (8). Phosphorylation of Tyr216 in GSK-3 regulates 
p53, which enhances Bax expression, resulting in cell death (9). 
GSK-3-mediated phosphorylation of Bax promotes its mi-
tochondrial localization, thus initiates neuronal apoptosis (10).
Apoptosis is crucial for recovery of damaged and infected 
cells (11); this mechanism is triggered through two signaling 
pathways, the intrinsic and extrinsic pathways (12, 13). The in-
trinsic mitochondrial pathway is initiated when pro-apoptotic 
signals from outside the cell are transmitted within the cell (12, 
13). This pathway hinges on the balance of activity between 
anti-and pro-apoptotic signals of the Bcl-2 family (14, 15). In 
the normal state, Bcl-2 combines with pro-apoptotic proteins 
(Bid, Bim, Bax, and Bak) and locates to the mitochondria. 
When an apoptotic signal from the outside is transmitted, the 
level of Bcl-2 is reduced, pro-apoptotic proteins combine with 
each other, the mitochondrial structure is changed, and apop-
tosis is initiated (14, 15). The extrinsic pathway occurs outside 
the cell through activation of pro-apoptotic receptors on the 
surface (6). Both pathways contribute to the activation of intra-
cellular cysteine proteases, referred to as caspases (6, 14, 15).
Paclitaxel is a well known and effective medicine for tumor 
chemotherapy; it is widely used against a broad range of can-
cers including breast, lung, and ovarian cancers (16, 17). 
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Fig. 1. Paclitaxel-mediated cell death is sensitive in MCF7 GSK-3
siRNA cell, compared to in MCF7 GFP control cell. MCF7 GFP con-
trol and MCF7 GSK-3 siRNA group were treated with paclitaxel (2
M) for 18 h. And then, cells were harvested and subjected to fol-
lowing assay, (A) using the Annexin V, (B) the DNA fragmentation,
and, (C) the TUNEL assay, to check cell death. The mean ± SEM 
values shown represent three independent experiments. **P ＜
0.01; ***P ＜ 0.001.
Fig. 2. Paclitaxel-induced decrease of Bcl-2 expression is sensitive in 
GSK-3 knockdown condition, JNK activity is crucial for paclitaxel- 
induced reduction of Bcl-2. MCF7 GFP control and MCF7 GSK-3
siRNA cells were incubated with paclitaxel (2 M) for 2 s. (A) Cells 
were harvested and immunoblotted with Bcl-2, Actin, and GSK-3
antibody. (B) Cells were fixed, permeablized, and stained with FITC- 
conjugated Bcl-2 antibody, and then stained with TO-PRO-3. (C) Cells
were incubated with paclitaxel (2 M) for 30 min, and harvested 
cells were subjected to immunnoblotting against p-JNK, JNK, p-p38, 
and, p38. (D) MCF7 GSK-3 siRNA cells were pre-treated with JNK 
inhibitor, SB600125 (25 M) or p38 inhibitor, SB203580 (10 M) for
30 min, and then cells were treated with paclitaxel (2 M) for 2 h. 
Cells were harvested and immunoblotted with Bcl- 2 and Actin. The
results are representative of three independent experiments.
Paclitaxel functions as a mitotic inhibitor, targeting microtubules 
(18, 19). Rodi et al. demonstrated that Bcl-2 was a target of pa-
clitaxel by screening a library of phage-displayed peptides (20).
Here, we demonstrate the absence of GSK-3 enhanced 
breast cancer cell death induced by paclitaxel. We also dem-
onstrate that paclitaxel-induced breast cancer cell death occurs 
through the intrinsic apoptosis pathway and is dependent on 
GSK-3 regulation of Bcl-2, using a GSK-3 siRNA system.
RESULTS
Paclitaxel-induced cell death is greater in MCF7 GSK-3 
siRNA cells than in MCF7 GFP control cells
In a previous report, we found that the level of apoptosis-signal 
regulating kinase 1 (ASK1) was regulated by GSK-3 (21). Thus, 
we investigated whether the presence of GSK-3 influences 
cell death in paclitaxel-stimulated conditions, using MCF7 
GSK-3 siRNA cells. First, we examined the cell death pop-
ulation change in MCF7 GFP control and MCF7 GSK-3 
siRNA cells by paclitaxel stimulation, using Annexin V/propi-
dium iodide (PI) staining. We observed that the population of 
Annexin V-stained cells in paclitaxel-treated MCF7 GSK-3 
siRNA cells was greater than in paclitaxel-treated MCF7 GFP 
control cells (Fig. 1A). We confirmed this observation using 
the TUNEL assay, showing a large increase in paclitaxel-in-
duced TUNEL-positive nuclei in the absence of GSK-3 (Fig. 
1C). Furthermore, in a DNA fragmentation assay, paclitaxel 
treatment resulted in greater DNA fragmentation in GSK-3 
knockdown cells (Fig. 1B) than in controls. From these results, 
we concluded that paclitaxel-induced breast cancer cell death 
was increased in GSK-3 knockdown cells.
Paclitaxel-induced Bcl-2 decrease is greater in the absence of 
GSK-3 and JNK activity is crucial for paclitaxel-induced 
reduction of Bcl-2
The Bcl-2 family of proteins is known as mediators of cell 
death, and an interaction between GSK-3 and Bcl-2 family 
proteins has been previously reported (8, 10). Because of the 
GSK-3-dependent differences in cell death observed, we ex-
amined the level of the anti-apoptotic protein Bcl-2 in MCF7 
GFP control and MCF7 GSK-3 siRNA cells. Fig. 2A shows 
that, in the absence of GSK-3, Bcl-2 levels are diminished; 
this is also the case with paclitaxel-induced decrease of Bcl-2 
in GSK-3 knockdown cells (Fig. 2A). These results were con-
firmed by confocal microscopy (Fig. 2B). In addition, we inves-
tigated paclitaxel-induced activation of MAPKs (JNK and p38) 
and found that paclitaxel-induced activation of these MAPKs is 
greater in MCF7 GSK-3 siRNA cells than in MCF7 GFP con-
trol cells (Fig. 2C). Furthermore, we found that JNK activity is 
critical for paclitaxel-mediated Bcl-2 modulation (Fig. 2D). 
From these results, we deduced that GSK-3 regulates Bcl-2 
levels in both basal and paclitaxel-treated cells, and that JNK 
activity is crucial for paclitaxel-induced reduction of Bcl-2.
Bcl-2 stability is reduced in the GSK-3 knockdown condition
In previous experiments, we found that GSK-3 regulates the 
level of Bcl-2 in paclitaxel-treated cells. Here, we performed 
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Fig. 3. The absence of GSK-3 reduces Bcl-2 stability. (A) MCF7 GFP control and MCF7 GSK-3 siRNA cells were treated with paclitaxel 
(2 M) for 45 and 90 min. (B) MCF7 GFP control and MCF7 GSK-3 siRNA cells were exposed to cylcloheximide (100 g/ml) for the in-
dicated times, and then cells were harvested and immunoblotted with indicated antibodies. The results are representative of three in-
dependent experiments. (C) MCF7 GFP control and MCF7 GSK-3 siRNA cells were harvested and immunoblotted with indicated antibodies.
(D) MCF7 cells were treated with GSK-3 inhibitor, SB415286 (25 M), for 30 min. Cells were harvested and performed immunoblot as-
say with Bcl-2 antibodies. (E) MCF7 GFP control and MCF7 GSK-3 siRNA cells were incubated with indicated doses of paclitaxel for 30 
min. Cells were harvested and subjected to immunnoblotting against GSK-3 (Ser9) and GSK-3 (Tyr216) antibody. (F) MCF7 GFP control 
and MCF7 GSK-3 siRNA cells were pretreated with proteasome inhibitor, MG132 (10 M), and then incubated with paclitaxel (2 M) for 
4 h. Bcl-2 ubiquitination was determined by immnoprecipitation with anti-Ub followed by immnoblotting with anti-Bcl-2. The results are 
representative of three independent experiments.
time course experiments to examine the stability of Bcl-2. As 
shown in Fig. 3A, Bcl-2 is stable in the presence of GSK-3 
during paclitaxel stimulation. However, in the absence of 
GSK-3, paclitaxel treatment resulted in decreased levels of 
Bcl-2 levels (Fig. 3A). Therefore, we investigated whether GSK- 
3 influenced the turnover rate of Bcl-2 in the presence of pa-
clitaxel using cycloheximide (CHX). We found that Bcl-2 is 
more stable in paclitaxel-treated cells in the presence of GSK- 
3, suggesting GSK-3-mediated Bcl-2 stabilization is resistant 
to proteosomal degradation (Fig. 3B). These results showed 
that GSK-3 plays a pivotal role in Bcl-2 stability under basal 
and paclitaxel-stimulated conditions. Most proteins degraded 
by the proteasome are dependent on ubiquitination (22). Due 
to the aberrant paclitaxel-mediated proteasomal degradation of 
Bcl-2 in the absence of GSK-3, we examined the effect of 
GSK-3 on the ubiquitination of Bcl-2. Consistent with pre-
vious stability data, in the absence or inhibition of GSK-3, 
more ubiquitinated Bcl-2 was observed than in the presence of 
GSK-3 (Fig. 3C, D). In addition, we observed paclitaxel-medi-
ated activation of GSK-3 via phosphorylations of Ser9 and 
Tyr216 residues (Fig. 3E). Furthermore, in paclitaxel-treated 
cells, a much stronger ubiquitination of Bcl-2 was detected in 
cells with GSK-3 knockdown compared to control cells (Fig. 
3F). Therefore, we concluded that GSK-3 activity is crucial for 
Bcl-2 ubiquitination under basal and paclitaxel-treated condi-
tions.
Paclitaxel-induced/stimulated/triggered cytochrome C 
release and mitochondrial membrane potential collapse are 
greater in MCF7 GSK-3 siRNA cells compared to MCF7 GFP 
control cells
Cytochrome C is an intermediate in apoptosis, a regulated 
form of cell death used to kill cells in response to infection, in 
the process of development, or DNA damage (23). In previous 
results, we found paclitaxel-induced cell death and aberrant 
Bcl-2 reduction in the absence of GSK-3. Therefore, we inves-
tigated paclitaxel-induced cytochrome C release and mito-
chondrial membrane potential in the presence or absence of 
GSK-3. MCF7 GFP control and MCF7 GSK-3 siRNA cells 
were treated with paclitaxel (2 M), incubated for 18 hours, 
and then harvested. Cytosolic and mitochondrial fraction as-
says using digitonin were performed. As shown in Fig. 4A, 
more cytochrome C release in the presence of paclitaxel was 
observed in MCF7 GSK-3 siRNA cells compared to MCF7 
GFP control cells. Mitochondrial membrane potential is an im-
portant barrier of apoptosis via cytochrome C release (24). Thus, 
we investigated whether paclitaxel treatment in the presence 
or absence GSK-3 affects the biochemical structure of mito-
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Fig. 4. Paclitaxel-induced cytochrome C 
release and mitochondrial potential col-
lapse are significant in MCF7 GSK- 3
siRNA cell, compared to those in 
MCF7 GFP control cell. MCF7 GFP 
control and MCF7 GSK3 siRNA cells 
were treated paclitaxel (2 M) for 18 h. 
(A) Cells were fractionated with mi-
tochondrial and cytosolic fractions. Each
fraction was subjected to immunoblot-
ted with indicated antibodies. (B) MCF7
GFP control and MCF7 GSK3 siRNA 
cells were treated paclitaxel (2 M) for 
18 h, and then cells were harvested 
and stained with DiOC6(3). The fluo-
rescence activity of DiOC6(3) was de-
termined by flow cytometory. The re-
sults are representative of three inde-
pendent experiments.
chondria. Paclitaxel-induced mitochondrial membrane poten-
tial collapse was greater in the absence of GSK-3 than in the 
presence of GSK-3 (Fig. 4B). From these results, we con-
cluded that GSK-3 functions as a barrier to cytochrome C re-
lease and mitochondrial membrane potential collapse in pacli-
taxel-stimulated cells.
DISCUSSION
In this work, we studied the synergistic effect of paclitaxel and 
GSK-3 siRNA in MCF7 breast cancer cells. GSK-3 functions 
as an important regulator of cell death induced by various 
stresses (6). Bcl-2 family members can be classified into three 
subfamilies based on functional and structural features (11), this 
family of proteins is localized to smooth endoplasmic reticulum 
and mitochondria and functions as anti-apoptotic proteins.
Interaction between GSK-3 and the Bcl-2 family proteins 
has been reported. GSK-3 exhibits pro-apoptotic effects by 
modulating Bax, a pro-apoptotic protein (10). GSK-3 inhibi-
tion evokes cell survival via CREB-dependent-Bcl-2 expression 
(8). In recent, it was reported that interleukin 17A inhibits au-
tophagy by blocking GSK-3-mediated Bcl-2 degradation (25). 
However, under conditions of paclitaxel treatment, the rela-
tionship between GSK-3 and Bcl-2 has not been addressed. 
Here, we investigated this question based on our previous re-
sults demonstrating that the level of apoptosis-signal regulating 
kinase 1 (ASK1) is regulated by GSK-3 (21). In addition, our 
and other group have been investigating on the relevance be-
tween GSK3 beta and MAPKs (21, 26-28).
Paclitaxel is a drug widely used in chemotherapy; it is a mi-
crotubule-targeting agent that is effective against a wide range 
of cancers (29). Paclitaxel-treated cells have defects in mitotic 
spindle assembly, chromosome isolation, and cell division (16, 
18, 30). In previous studies, Rodi et al. demonstrated that 
Bcl-2 was also a target of paclitaxel (20), a finding verified by 
demonstrating that the structure of Bcl-2 is similar to that of 
-tubulin (31). In this study, we showed that Bcl-2 could be an 
indirect target of paclitaxel via GSK-3.
Saunders et al. (32) first showed that paclitaxel could be an 
inducer of breast cancer cell death, and other works demon-
strated synergistic effects between paclitaxel and other anti-tu-
mor drugs in enhancing breast cancer cell death (33). In this 
study, we demonstrate an alternative mechanism to enhance 
the effects of paclitaxel on MCF7 breast cancer cells. We ob-
served that paclitaxel was more effective in killing breast can-
cer cells in the absence of GSK-3, using various cell death as-
says including Annexin V/propidium iodide (PI) staining, DNA 
fragmentation assay, and TUNEL assay. We also monitored 
Bcl-2 expression in paclitaxel-treated MCF7 GFP control and 
MCF7 GSK-3 siRNA cells and found that GSK-3 affected 
Bcl-2 levels in basal and paclitaxel-treated condition. In 
GSK-3 knockdown cells, Bcl-2 levels were reduced com-
pared with control cells. Bcl-2 levels were further reduced in 
paclitaxel-treated MCF7 GSK-3 siRNA cells compared with 
paclitaxel-treated MCF7 GFP control cells. We also showed 
that JNK activity is important for paclitaxel-mediated Bcl-2 
modulation. Furthermore, we observed that Bcl-2 stability is 
dependent on GSK-3 in the presence of paclitaxel and that 
GSK-3-mediated Bcl-2 stability is via ubiquitination pathway 
in basal and paclitaxel-stimulated conditions. Because Bcl-2 
levels are crucial for cytochrome C release, we investigated 
the effect of GSK-3 on cytochrome C release and mitochon-
dria membrane potential collapse under conditions of paclitax-
el treatment. From the series of experiments, we concluded 
that GSK-3 absence-mediated Bcl-2 reduction causes hy-
per-sensitive cell death of breast cancer by paclitaxol.
In future studies, we plan to define the detailed mechanism 
of GSK-3 inhibition-mediated Bcl-2 reduction and, to use this 
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information for therapeutic benefit to treat breast and other can-
cers using nano-particle and GSK-3 siRNA. This work should 
provide both better understanding and increased effectiveness 
of combined therapy using a GSK3 inhibitor and paclitaxel to 
accelerate the development of effective breast cancer drugs.
MATERIALS AND METHODS
Cell culture
MCF7 GFP control and MCF GSK-3 siRNA cells were kindly 
provided by Dr. Eui-ju Choi (Korea university, South Korea). 
Cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fe-
tal bovine serum, penicillin (100 U/ml), and streptomycin (100 
g/ml) under a humidified atmosphere of 5% CO2 at 37oC.
Reagents and antibodies
Antibodies against Bcl-2, Actin, GSK-3, cytochrome C, and 
COX4 were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). The anti-pJNK, anti-JNK, anti-pp38, and anti-p38 
were obtained from Cell Signaling Technology Inc. (Beverly, 
MA). Paclitaxol was purchased from Tocris Bioscience (Bristol, 
UK). DiOC6(3) was purchased from Enzo Life Sciences (Far-
mingdale, NY). Annexin V-FITC Apoptosis Detection Kit (BD 
Biosciences, Lexington, KY), TUNEL Assay Kit (Thermo Scien-
tific, Waltham, MA), and Subcellular Protein Fractionation Kit 
(Thermo Scientific, Waltham, MA) were used.
Detection of apoptosis
MCF7 GFP control and MCF GSK-3 siRNA cells (1 × 105 
cells) were were trypsinized, incubated with annexin V-FITC 
and propidium iodide (PI), and analysed by flow cytometry 
(FACSCalibur, BD Biosciences) with CellQuest software (BD 
Biosciences, Lexington, KY) for the detection of apoptotic cells 
(annexin V-positive, PI-negative). Abovementioned cells were 
also incubated with TUNEL reaction mixture for apoptosis 
analysis and then stained with DAPI. TUNEL-positive nuclei 
were analysed for apoptosis under analyzed by fluorescent mi-
croscope (Carl Zeiss Axiovert 200 fluorescence microscope, 
Germany). Data were expressed as the percentages of TUNEL- 
positive nuclei (the number of TUNEL-positive nuclei/the num-
ber of DAPI-stained nuclei × 100). DNA fragmentation was 
studied, using Cell Death Detection ELISA plus, as described 
by the manufacturer (Roche Diagnostics, Indianapolis, IN).
Western immunoblot analysis
Western bolt analysis was performed as previously described 
(34). In brief, cell lysates were subjected to SDS-PAGE and 
transferred to PVDF membranes. The PVDF membranes were 
then blocked with 5% nonfat milk in a washing buffer (50 mm 
Tris-HCl, pH 8.0, 150 mm NaCl, 0.1% Tween 20) and in-
cubated with the indicated antibodies for 1 h at room tem-
perature. The membranes were washed and incubated for 1 h 
at room temperature with the appropriate secondary antibodies 
conjugated with horseradish peroxidase (Thermo Scientific, 
Waltham, MA). Protein bands were visualized using an en-
hanced chemiluminescence system (Thermo Scientific, Wal-
tham, MA).
Subcellular fractionation
Briefly, MCF7 GFP control and MCF GSK-3 siRNA cells were 
harvested and trypsinized. The supernatant were removed and 
incubated with digitonin buffer (10 mM piperazine-N,N’-bis 
(ethanesulfonic acid) (PIPES), pH 6.8, 0.015% e/v digitonin, 
300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 5 mM EDTA, 
Protease inhibitor (Bio Basic Inc, Canada)) in the ice for 3 min, 
and then centrifuged 3 × 103 rpm for 10 min. The supernatant 
is cytosolic fraction and pellet is mitochondrial fraction.
Confocal laser scanning microscopy
MCF7 GFP control and MCF GSK-3 siRNA cells were seeded 
in the six-well plates for 24 h, and treated with paclitaxel for 
18 h. Cells were fixed in 4% formaldehyde for 15 min, and 
permeabilized with 0.1% Triton X-100 for 7 min. Next, cells 
were blocked with PBS containing 5% bovine serum albumin 
for 1 h and subjected to immunofluorescent staining with 
mouse anti-Bcl-2 polyclonal antibody for a further 2 h at room 
temperature or overnight at 4oC, and then followed by Alexa 
Fluor 488 anti-mouse IgG (H+L) (Invitrogen, Carlsbad, CA) for 
1 h at room temperature. Finally, fluorescence signals were an-
alyzed by confocal laser scanning microscope (LSM710, Carl 
Zeiss, Germany).
Assessment of m
m was assessed by measuring retention of the lipophilic 
cationic dye DiOC6(3) in mitochondria. Cells were harvested 
and incubated in a DiOC6(3) solution (20 nM in fresh medium) 
for 30 min at 37oC in the dark. The cells were then washed 
and resuspended in PBS. Immediately after PBS washing, m 
was measured by sorting the cells using FACSCalibur BD 
Biosciences, Lexington, KY). Dead cells were excluded by for-
ward and side-scatter gating. Data were acquired by analyzing 
an average population of 1 × 104 cells using CELLQuest soft-
ware BD Biosciences, Lexington, KY).
Statistical analysis
All experiments were repeated at least 3 times with consistent 
results. Unless otherwise stated, data were expressed as the 
mean ± SEM. Analysis of variance was used to compare ex-
perimental groups with control values, while comparisons be-
tween multiple groups were made using Tukey’s multiple 
comparison tests (Prism 3.0 GraphPad software). A P value less 
than 0.05 was considered to indicate statistical significance.
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